---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-029310"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:50:34.952548+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp

## Summary
- Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.
- Acquired assets generate ~$100M annual revenue; OPKO retains NY/NJ and oncology/urology ($400M).
- BioReference repaid $9.7M credit facility with JPMorgan; no prepayment penalty.
- Pro forma cash increases to ~$273M; estimated gain on sale ~$122.6M.
- OPKO Chairman cites transaction as key step toward profitability and focus on core testing.

## SEC filing metadata
- accession: 0001437749-24-029310
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/0001437749-24-029310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-029310
- JSON: https://secwatch.observer/filing/0001437749-24-029310.json
- Plain text: https://secwatch.observer/filing/0001437749-24-029310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.